Alphabet's Isomorphic Labs Secures $5 Billion for AI Drug Discovery Platform
Alphabet's drug discovery spinout Isomorphic Labs has secured $5 billion in a Series C funding round to accelerate clinical trials and expand its AI platform.
🤖AI ModelsPhoto: thenextweb.com
Key points
- Isomorphic Labs raised $5 billion in a Series C funding round co-led by Sequoia Capital and Greenoaks.
- The capital will accelerate clinical trials and expand drug design capabilities into large-molecule biologics.
- The company maintains active partnerships with major pharmaceutical firms including Eli Lilly, Novartis, and Johnson & Johnson.
Isomorphic Labs, an Alphabet-backed drug discovery enterprise led by Demis Hassabis, announced a $5 billion Series C funding round co-led by Sequoia Capital and Greenoaks. The fresh capital arrives just six months after the firm secured a $2.1 billion investment in May, with additional participation from Andreessen Horowitz and continued backing from Alphabet alongside existing backers like Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
While the company did not officially reveal its corporate valuation, recent financial reports suggest the round values the enterprise at approximately $50 billion. Hassabis stated that the proceeds will primarily accelerate the firm's transition into clinical trials, with the ultimate objective of developing a platform capable of engineering hundreds of pharmaceutical candidates annually. The organization currently manages over 20 active pipelines spanning oncology and immunology, including collaborative projects with major drugmakers such as Eli Lilly, Novartis, and Johnson & Johnson.
Building upon the foundational success of Google DeepMind's AlphaFold protein structure model, Isomorphic plans to scale its proprietary IsoDDE drug design engine beyond conventional small-molecule therapeutics into diverse biological modalities, including large-molecule biologics. Although no regulatory body has yet approved an entirely AI-engineered medicine, Hassabis confirmed that the company remains on schedule with its regulatory submissions and development milestones.
What to watch next: Monitor the progression of Isomorphic's upcoming regulatory filings as the company moves toward its anticipated clinical trial phase.
Source thenextweb.com — thenextweb.com/news/isomorphic-labs-5bn-series-c-sequoia-greenoaks ↗
Read next
🌐Work & SocietyAmbience Healthcare Expands Clinical AI Suite for Hospital Operations
Ambience Healthcare has launched new AI tools designed to assist hospital staff with patient rounding and discharge planning, aiming to improve both clinical efficiency a…
🧠AI AnalysisAI Models Vulnerable to Manipulation in Simulated Warfare Scenarios, Research Shows
New research reveals that leading AI models from firms like OpenAI and Anthropic can be manipulated into identifying civilian targets when prompted with game scenarios.
⚖️Regulation & PolicyAWS Highlights Enterprise Governance and AI Workspace Quick Ahead of re:Invent 2026
Amazon Web Services is spotlighting its workplace AI platform, AWS Quick, ahead of its upcoming re:Invent 2026 conference, emphasizing secure deployment across major ente…
🏢Big TechLoanPro Integrates Amazon Bedrock to Automate Loan Servicing Workflows
LoanPro has deployed a multi-agent AI assistant using Amazon Bedrock and Anthropic's Claude models to help lenders manage borrower accounts, resulting in a 15% reduction …
🏢Big TechGoogle Brings Wallet App to iOS Users Across the United States
Google has expanded the availability of its Wallet application to iOS devices in the U.S., allowing Apple users to store digital passes, tickets, and receipts.
⚖️Regulation & PolicyMicrosoft Reveals Cause of Global Outlook Outage
A latent software bug caused a nearly 24-hour global outage of Microsoft’s Exchange Online services, affecting millions of users worldwide.